Harrison.ai, a global leader in AI-powered medical diagnostics and workflow solutions, has announced a $112 million Series C funding round. The investment will accelerate the company’s expansion into the United States and support its growth in key regions such as the UK, EMEA, and APAC. This latest round marks one of the largest capital raises in the medical AI sector over the past year, reinforcing the company’s mission to enhance clinical efficiency and improve early disease detection.

Funding and Investor Participation

The Series C round was co-led by Aware Super, ECP, and existing investor Horizons Ventures, with participation from new backers including Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett, and Wollemi Capital Group. Existing investors such as Blackbird Ventures and Alpha JWC Ventures also contributed, bringing Harrison.ai’s total capital raised to over $240 million. The funding will be used to advance its product roadmap, enhance AI-driven healthcare technologies, and strengthen its presence in global markets.

Expanding AI’s Role in Healthcare

Harrison.ai specializes in AI-driven radiology and pathology solutions designed to assist clinicians in detecting critical illnesses such as cancer at earlier stages. By analyzing medical imaging data, including CT scans, X-rays, and pathology slides, its technology enhances diagnostic accuracy and accelerates decision-making for healthcare professionals. The company aims to address the global shortage of skilled medical professionals, particularly in regions with a high demand for diagnostic services.

Addressing Healthcare Workforce Challenges

The global healthcare sector faces a shortage of approximately 1.5 million skilled clinicians, a gap that AI-driven solutions can help bridge. In the United States, there are only 11 radiologists per 100,000 people, and over two-thirds of the world’s pathologists are concentrated in just 10 countries. Harrison.ai’s AI solutions are positioned to alleviate this strain by optimizing workflows and increasing clinical efficiency, allowing healthcare providers to manage patient demand more effectively.

Clinical Impact and Technological Advancements

Harrison.ai’s technology has demonstrated substantial improvements in early disease detection and diagnostic accuracy. Studies have shown that its AI-driven chest radiography tools could have led to earlier lung cancer diagnoses in over 32% of cases, with an average detection time reduced by 16 months. Additionally, the company’s radiology platform has increased diagnostic accuracy for lung cancer detection by over 45%, contributing to better patient outcomes and more effective treatment plans.

Global Reach and Future Expansion

Currently, over 1,000 healthcare facilities worldwide use Harrison.ai’s technology, impacting more than six million patients annually. In Australia, its radiology solution, Annalise.ai, is utilized by half of the country’s radiologists, while in the UK, it supports diagnostics in over 131 public hospitals and processes 35% of England’s chest X-ray volume. The company is further expanding its footprint in Hong Kong and Denmark while setting up a new North American base in Boston to facilitate U.S. market entry.

Regulatory Milestones and Industry Collaboration

Harrison.ai has received 12 FDA clearances, with one of its CT Brain algorithms earning FDA Breakthrough Device Designation and Medicare reimbursement approval. Its radiology-specific vision-language technology, Harrison.rad.1, is now accessible to researchers, regulators, and AI industry partners. The company has also been invited to join the Healthcare AI Challenge hosted by Mass General Brigham, collaborating with major tech players such as Microsoft, OpenAI, and Google to assess and refine AI applications in medical imaging.

With its latest funding and strategic expansion into the U.S., Harrison.ai is poised to transform AI-driven medical diagnostics on a global scale. By leveraging advanced AI technologies, the company aims to address clinician shortages, improve early disease detection, and enhance healthcare efficiency worldwide. As it continues to innovate and expand, Harrison.ai is set to play a pivotal role in shaping the future of AI-powered healthcare solutions.